» Articles » PMID: 36836078

Multidisciplinary Guidelines for the Rational Use of Topical Non-Steroidal Anti-Inflammatory Drugs for Musculoskeletal Pain (2022)

Abstract

(1) Background: Topical non-steroidal anti-inflammatory drugs (NSAIDs) are one of the primary drugs for treating musculoskeletal pain. However, there are currently no evidence-based recommendations about drug selection, drug administration, drug interactions, and use in special populations or other pharmacology-related content of such medications. To this end, the Chinese Pharmaceutical Association Hospital Pharmacy Professional Committee developed multidisciplinary guidelines on using topical NSAIDs to treat musculoskeletal pain. (2) Methods: The guidelines development process followed the World Health Organization guideline development handbook, the GRADE methodology, and the statement of Reporting Items for Practice Guidelines in Healthcare. The guideline panel used the Delphi method to identify six clinical questions to be addressed in the guidelines. An independent systematic review team conducted a systematic search and integration of evidence. (3) Results: Based on the balance between the benefits and harms of an intervention, the quality of the evidence, patient preferences and values, and resource utilization, the guideline panel developed 11 recommendations and nine expert consensuses on using topical NSAIDs to treat acute and chronic musculoskeletal pain. (4) Conclusions: Based on the effectiveness and overall safety of topical NSAIDs, we recommend patients with musculoskeletal pain use topical NSAIDs and suggest high-risk patients use topical NSAIDs, such as those with other diseases or receiving other concurrent treatments. The evidenced-based guidelines on topical NSAIDs for musculoskeletal pain incorporated a pharmacist perspective. The guidelines have the potential to facilitate the rational use of topical NSAIDs. The guideline panel will monitor the relevant evidence and update the recommendations accordingly.

Citing Articles

Making Sense of Topical Pain Relief Options: Comparing Topical Analgesics in Efficacy and Safety.

Smith A, Smith M, Roach R, Prine B, Moser M, Farmer K Sports Health. 2024; :19417381241280593.

PMID: 39460722 PMC: 11556579. DOI: 10.1177/19417381241280593.


Microemulsion-Based Polymer Gels with Ketoprofen and Menthol: Physicochemical Properties and Drug Release Studies.

Otto F, Froelich A Gels. 2024; 10(7).

PMID: 39057458 PMC: 11275338. DOI: 10.3390/gels10070435.


Efficacy and Safety of Loxoprofen Sodium Hydrogel Patch in Patients with Chronic Inflammatory Pain: A 4-Week Real-World Study.

Chen Y, Bian X, Wang J, Yan F, Gao J, Sun T J Pain Res. 2024; 17:535-541.

PMID: 38343655 PMC: 10857902. DOI: 10.2147/JPR.S437462.

References
1.
Yataba I, Otsuka N, Matsushita I, Matsumoto H, Hoshino Y . The efficacy and safety of S-flurbiprofen plaster in the treatment of knee osteoarthritis: a phase II, randomized, double-blind, placebo-controlled, dose-finding study. J Pain Res. 2017; 10:867-880. PMC: 5396977. DOI: 10.2147/JPR.S131779. View

2.
Roth S, Fuller P . Pooled safety analysis of diclofenac sodium topical solution 1.5% (w/w) in the treatment of osteoarthritis in patients aged 75 years or older. Clin Interv Aging. 2012; 7:127-37. PMC: 3393357. DOI: 10.2147/CIA.S30884. View

3.
Predel H, Pabst H, Schafer A, Voss D, Giordan N . Diclofenac patch for the treatment of acute pain caused by soft tissue injuries of limbs: a randomized, placebo-controlled clinical trial. J Sports Med Phys Fitness. 2015; 56(1-2):92-9. View

4.
Hekmatpou D, Mortaji S, Rezaei M, Shaikhi M . The Effectiveness of Olive Oil in Controlling Morning Inflammatory Pain of Phalanges and Knees Among Women With Rheumatoid Arthritis: A Randomized Clinical Trial. Rehabil Nurs. 2018; 45(2):106-113. DOI: 10.1097/rnj.0000000000000162. View

5.
Zhao D, Chen Z, Hu S, Lin J, Shao Z, Wang G . Efficacy and Safety of Loxoprofen Hydrogel Transdermal Patch Versus Loxoprofen Tablet in Chinese Patients with Myalgia: A Double-Blind, Double-Dummy, Parallel-Group, Randomized, Controlled, Non-Inferiority Trial. Clin Drug Investig. 2019; 39(4):369-377. PMC: 6443607. DOI: 10.1007/s40261-019-00756-x. View